Creative Medical Technology Holdings Inc (OTCMKTS: CELZD) Gets the Extra D – MicroCap Daily

Creative Medical Technology Holdings Inc (OTCMKTS: CELZD) is the new temporary ticker symbol for Creative Medical since the Company affected a 1 for 150 reverse stock split. According to the Company the reverse split of our stock was a decision that did not come lightly. In order to secure more competitive financing terms and to reduce existing convertible debt, the company needed to return to the OTCQB. As the fundamentals of the company continue to expand and commercialization is ramped up, this was determined to be necessary for the long-term benefit to the company and its shareholders. The reverse affected ALL shareholders, including founding shareholders, Officers and Directors, who have substantial holdings in CELZ stock as well said Timothy Warbington CEO.

Microcapdaily has been reporting on CELZ for years; on November 18, 2018 we stated: CELZ is an exciting stock that has attracted legions of shareholders who see big things happening here. CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. CELZ has runner in its blood and a long history of huge moves skyrocketing from $0.002 in March of last year to highs topping $0.07 per share in August, CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB.

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ)is a commercial-stage biotechnology company focused on Urology and Neurology using stem cell treatments. The companys team consists of leading international researchers in regenerative medicine with a science-first approach to treatments ensuring that all of its treatments are proven to be both safe and effective. CELZ is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (ED) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (LABIOMED), for the infertility treatment. It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED.

To Find out the inside Scoop on CELZD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Creative Medical is currently in the commercial stage of its bone marrow based stem cell treatment for Erectile Dysfunction known as CAVERSTEM, which is being marketed both nationally, and internationally. Earlier this year the Company formed the subsidiary CaverStem International LLC for the purpose of commercializing its erectile dysfunction technology to international physicians.

In a recent update on StemSpine Thomas Ichim PhD of CELZ stated StemSpine will surely be welcomed by the over 50 million Americans suffering from CLBP in the United States as a drug free alternative. Currently, there are minimal treatment options for patients that suffer from this debilitating pain, with roughly 50% of patients progressing to opioids and surgery. I have been thrilled with the positive reception of StemSpine across all fronts as we quietly progressed the program forward over the last few months, said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. I am especially energized by the positive reception from potential healthcare providers who have overwhelmingly confirmed this is a necessary and highly desirable alternative to current treatment options. We look forward to partnering with these providers and bringing this therapy to the forefront in 2020 for the benefit of the many patients that stand to benefit from it and for our shareholders as we think it will drive tremendous value for the organization.

We have a Monster Pick Coming. Subscribe Right Now!

Currently on the move since affecting a 1 for 150 reverse CELZ is fully reporting OTCBB, has minimal cash in the treasury, $3.9 million in current liabilities and some revenues reporting $169k in sales in 2019. we stated in 2016: CELZ is an exciting Company developing in small caps; CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB.We will be updating on CELZ when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with CELZ.

Disclosure: we hold no position in CELZ either long or short and we have not been compensated for this article.

Continue reading here:
Creative Medical Technology Holdings Inc (OTCMKTS: CELZD) Gets the Extra D - MicroCap Daily

Related Posts